NCT04795245

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

J-REGISTER: Japanese REal-world Data for Treatment of Afatinib (GIotrif®) in First-line Setting and Subsequent Therapies for Patients With Advanced EGFR Mutation-positive Lung Adenocarcinoma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 805 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to confirm Time on Treatment (TOT) related to afatinib treatment as first-line therapy in patients with Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC). The observation in the real-world setting of the time from the start of the first-line afatinib until the end of subsequent treatment in this study will provide insights on the sequence of treatment for patients. The Japanese healthcare system will enable this study to evaluate multiple treatment options after afatinib treatment.

Conditions

• Non-squamous, Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	afatinib	afatinib

Timeline

• Start date: 2021-08-26
• Primary completion: 2023-10-16
• Completion: 2023-10-16
• First posted: 2021-03-12
• Last updated: 2024-12-27
• Results posted: 2024-12-27

Locations

1 site across 1 country: Japan